



Andrew J. Cochran

PARTNER

acochran@cahill.com

212.701.3320 Phone

Cahill Gordon & Reindel LLP

32 Old Slip

New York, NY 10005

Andrew (Andy) Cochran is a partner in the New York office of Cahill Gordon & Reindel LLP.

While Andy has a versatile range of experience in high-stakes patent matters involving a variety of technologies, including enterprise content management software, enterprise file sharing and sync software, microchip technology, and medical devices, he focuses his practice mainly on complex patent litigation matters involving pharmaceuticals, biotechnology, and biologics/biosimilars both in federal court and before the Patent Trial and Appeal Board of the U.S. Patent Office. Andy also has an extensive patent prosecution background that has encompassed an array of technologies, including automotive hybrid systems, medical devices, consumer products, and oncology.

Andy is a contributor to the “Intellectual Property Issues for Pharmaceutical Manufacturers” chapter in Fastcase’s *Regulation of Pharmaceutical Manufacturers* (2020). Andy was also featured in the 2024 edition of *Best Lawyers’* “Ones to Watch” in the area of patent litigation.

Matters

- Representing Galderma in Hatch-Waxman litigation relating to Oracea®, a once-daily doxycycline product used to treat rosacea
- Representing an individual inventor in patent litigation involving a novel microchip
- Represented large software company in competitor-vs-competitor, multi-district patent litigation on enterprise content management software*
- Represented pharmaceutical company in BPCIA litigation regarding a biosimilar to monoclonal antibody product, Humira®*
- Represented the patent owner in an inter partes review regarding a long-acting pharmaceutical product used to treat alcohol and opioid dependence*
- Represented a pharmaceutical company in Hatch-Waxman litigation involving Entereg, an oral pharmaceutical product for the treatment of post-operative ileus*
- Represented a pharmaceutical company in Hatch-Waxman litigation involving an extended-release product used to treat the gastrointestinal disorder, ulcerative colitis*

**Matter handled prior to joining Cahill.*

Professional Activities

Associations

- New York Intellectual Property Law Association (NYIPLA)

Education

Fordham University School of Law, J.D., 2013

Ohio State University, M.S., 2008

Ohio State University, B.S., 2006

Practices

Life Sciences Patent Litigation

Intellectual Property Litigation

Intellectual Property

Life Sciences

Admissions

New York

U.S. Patent and Trademark Office

U.S. Court of Appeals for the Federal Circuit

U.S. District Court for the Eastern District of Texas